APAC Vaccine Adjuvant Market

APAC Vaccine Adjuvant Market Size

The Asia-Pacific Vaccine Adjuvant Market is projected to grow from USD 130.17 million in 2025 to USD 145.43 million in 2026 and reach USD 353.20 million by 2034, registering a CAGR of 11.73% during the forecast period from 2026 to 2034.

Vaccine adjuvants are desirable to expand the adaptive immune reactions to antigens. Adjuvants show their effects through diverse mechanisms. Some adjuvants work as delivery systems that provide stimulation of the immune system. Immunologic adjuvants are added to vaccines for the stimulus of the immune system's reaction to the target antigen but directly do not offer immunity. Adjuvants may act in several ways to present an antigen in the immune system. Adjuvants may also serve as the annoyance to involve and intensify the body's immune response.

Factors driving the world vaccine adjuvants market are increasing government funding in R&D, the high occurrence of diseases, the growing emphasis on improved vaccines, and progressive strategic moves assumed by companies such as contracts, acquisitions, and associations.

However, the side effects of adjuvants and the cost of adjuvant growth restrict the market growth.

This research report on the APAC vaccine adjuvant market has been segmented and sub-segmented into the following categories:

By Type:

• Aluminum Salts
• Tensoactive Adjuvants
• Adjuvant Emulsions
• Bacteria Derived Adjuvants
• Liposome Adjuvants
• Carbohydrate Adjuvants

By Route Of Administration:

• Oral
• Intradermal
• Subcutaneous
• Intranasal
• Intramuscular

By Mechanism Of Action:

• Immuno Stimulants
• Carriers
• Vehicle Adjuvants

By Country:

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Regionally, China, and India, being developing countries with an increase in population, are estimated to grow at the highest CAGR in the forecast period.

The Indian vaccine adjuvant market accounted for the largest share in the Asia Pacific market in 2021. The World health organization (WHO) estimated that there are 15 million malaria cases, with 19000-20000 deaths every year in India. In 2021, the collaboration between Novavax and the serum institute of India had introduced a next-generation commercial vaccine adjuvant to treat infectious diseases. Therefore, it helps to boost the Indian vaccine adjuvant market. Recently, the Indian government developing its drug discovery and innovation in vaccine adjuvant with collaboration with the US research center is driving the growth of the Indian vaccine adjuvant market.

In China, Biodegradable nanomaterial and nanotechnology have played a crucial role in developing vaccine adjuvants due to their application, such as better immune effect, less toxic, and dose accuracy, driving the growth of the Chinese population vaccine adjuvant market. Also, rising coronavirus patients in china and development in healthcare industries like CpG 1018 product offering to boost immune response in China is fuelling the market's growth. In addition, China has the most massive burden of Hepatitis-B disease. Nearly 70 million people infected by this disease in 2018 are propelling the growth of the vaccine adjuvants market in China.

The new vaccine and adjuvant center were established in Japan to develop an immune response against disease and other diseases such as Alzheimer’s, hypertension, and epilepsy. As a result, the Japanese vaccine adjuvants market is estimated to project a healthy CAGR during the forecast period.

KEY MARKET PLAYERS:

Companies playing a leading role in the APAC vaccine adjuvant market profiled in this report are MPV Technologies, Avanti Polar Lipids, Novavax Inc. Brenntag Biosector, SEPPIC, Agenus, Inc., Invivogen, SPI Pharma, Inc., CSL Limited, and OZ Biosciences.